Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

SSRI produces significant improvements in patients with social phobia

Aug. 26, 1998

Parke-Davis synthesizes potent and selective D4 ligands with antipsychotic potential

Aug. 26, 1998

Allelix research into antimigraine compounds proves fruitful

Aug. 26, 1998

Neuroprotective glutamate receptor antagonists disclosed by Warner-Lambert

Aug. 26, 1998

Dual 5-HT reuptake inhibitors/5-HT1A antagonists with potential as antidepressants

Aug. 26, 1998

Pagoclone reduces frequency of panic attacks in patients with panic disorder

Aug. 26, 1998

Disappointing results obtained in phase II/III trial of LU-25-109T

Aug. 25, 1998

Bristol-Myers Squibb discovers novel maxi-K channel openers

Aug. 25, 1998

Novel cysteine protease inhibitors discussed by BASF

Aug. 24, 1998

HemispheRx announces first regulatory filing for CFS/ME treatment agent

Aug. 21, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...